Pulmonary fibrosis in patients with COVID-19: A review
The viral infectious disease pandemic caused by SARS-CoV-2 has affected over 500 million people and killed over 6 million. This is the official data provided by the WHO as of the end of May 2022. Among people who have recovered from COVID-19, post-COVID syndrome is quite common. Scattered epidemiolo...
Main Author: | Alexander G. Chuchalin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
"Consilium Medicum" Publishing house
2022-12-01
|
Series: | Терапевтический архив |
Subjects: | |
Online Access: | https://ter-arkhiv.ru/0040-3660/article/viewFile/119999/94765 |
Similar Items
-
Pharmacological approaches to pulmonary fibrosis following COVID-19
by: Stefan Lassan, et al.
Published: (2023-06-01) -
Idiopathic Pulmonary Fibrosis and Post-COVID-19 Lung Fibrosis: Links and Risks
by: Filippo Patrucco, et al.
Published: (2023-03-01) -
Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study
by: Yuzo Suzuki, et al.
Published: (2021-07-01) -
Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single‐arm, open‐label nonrandomized study
by: Dariusz Jastrzębski, et al.
Published: (2023-08-01) -
The Genesis of Dyspnea in Patients After COVID-19
by: Pozdnyakova, T.D., et al.
Published: (2023-08-01)